RongCan Biotech Signed a Strategic Cooperative Agreement on Clinical Research Services with Shanghai Clinical Research Centre (SCRC)

Focusing on the development and industrialization of nucleic acid medicines

Focusing on the development and industrialization of nucleic acid medicines

Focusing on the development and industrialization of nucleic acid medicines

Possesses a proprietary RNA-based Therapeutic Platform (RTP) independently developed for nucleic acid medicines

RongCan Biotech Signed a Strategic Cooperative Agreement on Clinical Research Services with Shanghai Clinical Research Centre (SCRC)

Date : 2021-09-16

Prev : RongCan Biotech Won the Second Prize at the Anhui Selective Trial of China Innovation and Entrepreneurship Competition

Next : RongCan Biotech Has Cooperated with the School of Pharmacy at Shanghai Jiao Tong University to Establish a Joint Research Centre